Prognica and Pinnacology Partner for Anxiety Therapy
The companies aim to co-develop an investigational intranasal microemulsion therapy for treating anxiety disorders.
Updated on Oct. 22, 2026 in Wellness
Live Poll
Do you trust that pharmaceutical companies prioritize patient needs over the potential size of a market?
Dubai-based Prognica Labs and India-based Pinnacology Research & Development have formed a strategic partnership to create a new anxiety treatment. The collaboration combines AI-enabled drug discovery with specialized formulation research to develop an intranasal microemulsion therapy.
Why it matters
Current anxiety treatments often take weeks to become effective or pose risks like sedation and dependence, driving the need for faster-acting alternatives. This partnership seeks to leverage phytochemicals to bridge the gap in existing mental health care options.
The global anxiety disorders treatment market was valued at US$12.3 billion in 2025 and is projected to reach US$17.6 billion by 2035. This growth represents an estimated compound annual growth rate of 3.6%.
The players
Prognica Labs
A company headquartered in Dubai that specializes in AI-enabled drug discovery.
Pinnacology Research & Development
An India-based organization focused on research and formulation development.
The details
The investigational therapy uses a combination of phytochemicals, including flavan-3-ols, and aromatic resin extracts. Prognica Labs will manage the development strategy and computational evaluation, while Pinnacology provides the underlying formulation research.
Timeline
In 2021, approximately 359 million people globally lived with anxiety disorders.
The global anxiety treatment market was valued at US$12.3 billion in 2025.
Prognica Labs and Pinnacology announced their partnership on 2026-10-22.
The global anxiety treatment market is projected to reach US$17.6 billion by 2035.
Health Landscape
This development represents a shift toward novel delivery mechanisms for mental health conditions, contrasting with standard pharmaceutical models. The therapy marks a potential departure from the historical reliance on selective serotonin reuptake inhibitors for anxiety treatment by focusing on rapid-acting intranasal delivery.
The investigational treatment is currently in the research phase and is not available for clinical use or purchase. Patients should continue to follow existing medical guidance from healthcare providers until new therapies are proven safe and effective.
The takeaway
This partnership highlights the growing integration of AI and botanical research in the search for better mental health outcomes. Ongoing clinical testing will determine whether these new microemulsion formulations can offer a viable alternative to existing medications.
Further reading
For more information on the evolving state of mental health care, visit the Wellness section.
Live Poll
Do you trust that pharmaceutical companies prioritize patient needs over the potential size of a market?
